Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Thyroid ; 32(7): 764-771, 2022 07.
Article in English | MEDLINE | ID: mdl-35570696

ABSTRACT

Background: Combination therapy with liothyronine (LT3) and levothyroxine (LT4) is used in patients with persistent symptoms, despite being administered an adequate dose of LT4. LT3 may also be used in some thyroid cancer patients preparing for radioactive iodine therapy. However, there is a controversy regarding the safety of LT3 use, and there has been no definite evidence of long-term safety of LT3 therapy in Asian populations. The aim of this study was to examine the long-term safety of LT3 therapy using the Common Data Model (CDM). Methods: We conducted a retrospective multicenter study across four hospital databases encoded in the Observational Medical Outcomes Partnership (OMOP) CDM. LT3 users were defined as those who received an LT3 prescription for at least 90 days (with or without LT4), and their safety outcomes were compared with those in LT4-only users after 1:4 propensity score matching. Safety outcomes included the incidences of osteoporosis, cardiovascular disease, cancer, anxiety disorder, and mood disorder. Results: We identified 1434 LT3 users and 3908 LT4-only users. There was a statistically significant difference in the incidence rate of safety outcomes between LT3 users and LT4-only users. The risks of heart failure (incidence rate ratio [IRR] = 1.664, 95% confidence interval [95% CI] 1.002-2.764, p = 0.049) and stroke (IRR = 1.757, CI 1.073-2.877, p = 0.025) were higher in LT3 users than in LT4-only users. When subgroup analysis was performed according to the presence/absence of thyroid cancer history and duration of thyroid hormone replacement, the risk of heart failure was higher in LT3 users with a history of thyroid cancer and those who underwent ≥52 weeks of LT3 therapy. In addition, the risk of stroke was higher in LT3 users without thyroid cancer history and those who underwent ≥52 weeks of LT3 therapy. Conclusions: The use of LT3 was associated with increased incidence of heart failure and stroke in patients with a longer duration of LT3 use and history of thyroid cancer. Therefore, clinicians should consider the risk of heart failure and stroke in thyroid cancer patients with long-term use of LT3. These findings require confirmation in other populations.


Subject(s)
Heart Failure , Hypothyroidism , Stroke , Thyroid Neoplasms , Heart Failure/epidemiology , Humans , Hypothyroidism/drug therapy , Iodine Radioisotopes/therapeutic use , Propensity Score , Stroke/epidemiology , Stroke/etiology , Thyroid Neoplasms/drug therapy , Thyrotropin/therapeutic use , Thyroxine/therapeutic use , Triiodothyronine/therapeutic use
3.
Sci Rep ; 12(1): 387, 2022 01 10.
Article in English | MEDLINE | ID: mdl-35013484

ABSTRACT

We evaluated the associations between metabolic parameters with visceral adipose tissue (VAT) volume in women with prediabetes or type 2 diabetes (T2DM), and we compared the VAT volume with the VAT area. We enrolled women aged > 20 years with prediabetes or T2DM, who underwent oral glucose tolerance test and whose VAT was evaluated using computed tomography (CT) at our institution between 2017 and 2019. All participants underwent unenhanced spiral CT with a 3-mm slice thickness from the level of the diaphragm to the level of the mid-thigh. The two VAT areas were defined as the free drawn area on the levels of the umbilicus and L2 vertebra. The VAT areas were also manually drawn from the level of the diaphragm to the level of the pelvic floor and were used to calculate the VAT volumes by summing all areas with a slice thickness of 3 mm after setting the attenuation values from -45 to -195 Hounsfield Unit. All metabolic characteristics, except blood pressure, were significantly correlated with the VAT volume. The VAT areas measured at the level of the L2 vertebra and umbilicus were correlated with serum triglyceride, high-density lipoprotein cholesterol, and Framingham steatosis index alone. Multivariable regression analyses revealed that the VAT volume was significantly associated with several metabolic parameters. In conclusion, in women with prediabetes and T2DM, the VAT volume acquired from CT-based calculation has more significant correlations with metabolic risk factors compared with the VAT area.


Subject(s)
Adiposity , Diabetes Mellitus, Type 2/diagnostic imaging , Intra-Abdominal Fat/diagnostic imaging , Metabolic Syndrome/diagnostic imaging , Prediabetic State/diagnostic imaging , Tomography, Spiral Computed , Aged , Biomarkers/blood , Blood Glucose/metabolism , Cardiometabolic Risk Factors , Cholesterol, HDL/blood , Cross-Sectional Studies , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/physiopathology , Fatty Liver/blood , Fatty Liver/diagnostic imaging , Fatty Liver/physiopathology , Female , Glucose Tolerance Test , Humans , Insulin Resistance , Intra-Abdominal Fat/physiopathology , Metabolic Syndrome/blood , Metabolic Syndrome/physiopathology , Middle Aged , Prediabetic State/blood , Prediabetic State/physiopathology , Predictive Value of Tests , Retrospective Studies , Risk Assessment , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...